- Author: Jason L Huffman, MD; Chief Editor: BS Anand, MD more...
Chronic pancreatitis is commonly defined as a continuing, chronic, inflammatory process of the pancreas, characterized by irreversible morphologic changes.
Essential update: AGA releases new guidelines for diagnosis/management of asymptomatic neoplastic pancreatic cysts
The American Gastroenterological Association recommends the following in the diagnosis and management of asymptomatic neoplastic pancreatic cysts :
For asymptomatic mucinous cysts, a 2-year interval is recommended for a cyst of any size undergoing surveillance, with surveillance being stopped after 5 years if there is no change.
Perform surgery only if there is more than one concerning feature on MRI confirmed on endoscopic ultrasonography (EUS) and only in centers with high volumes of pancreatic surgery, and there should be no surveillance after surgery if there is no invasive cancer or dysplasia.
The risk of malignant transformation of pancreatic cysts is approximately 0.24% per year, and the risk of cancer in cysts without a significant change over a 5-year period is likely to be lower.
The small risk of malignant progression in stable cysts is likely outweighed by the costs of surveillance and the risks of surgery.
Positive cytology on EUS-guided fine-needle aspiration (FNA) has the highest specificity for diagnosing malignancy; if there is a combination of high-risk features on imaging, then this is likely to increase the risk of malignancy even further. Similarly, if a cyst has both a solid component and a dilated pancreatic duct (confirmed on both EUS and MRI), the specificity for malignancy is likely to be high even in the absence of positive cytology.
There is lower immediate postoperative mortality, as well as long-term mortality, for patients who undergo surgery in high-volume pancreatic centers.
It seems sensible to offer screening even after the cyst has been resected, provided the patients have not undergone total pancreatectomy. Surveillance should continue as long as the patient remains a good candidate for surgery. MRI every 2 years may be a reasonable approach for these patients. The clinician may elect to offer more frequent surveillance in the case of invasive cancer resection, particularly if there is concern that the lesion has not been fully resected.
Signs and symptoms
For most patients with chronic pancreatitis, abdominal pain is the presenting symptom. The patient experiences intermittent attacks of severe pain, often in the mid-abdomen or left upper abdomen and occasionally radiating in a bandlike fashion or localized to the midback. The pain may occur either after meals or independently of meals, but it is not fleeting or transient and tends to last at least several hours.
Other symptoms associated with chronic pancreatitis include diarrhea and weight loss.
See Clinical Presentation for more detail.
Diagnosis is based on tests of pancreatic structure and function.
Imaging studies such as abdominal radiography and CT scanning can show inflammation or calcium deposits of the pancreas or changes in the pancreatic ducts. Pancreatic calcifications, often considered pathognomonic of chronic pancreatitis, are observed in approximately 30% of cases.
Endoscopic retrograde cholangiopancreatography
The endoscopic retrograde cholangiopancreatography (ERCP) test provides the most accurate visualization of the pancreatic ductal system and has been regarded as the criterion standard for diagnosing chronic pancreatitis. It combines the use of endoscopy and fluoroscopy to visualize and treat problems of the bile and pancreatic ducts. See the image below.
Magnetic resonance cholangiopancreatography
MRCP provides information on the pancreatic parenchyma and adjacent abdominal viscera, and it uses heavily T2-weighted images to visualize the biliary and pancreatic ductal system. This procedure is relatively safe, reasonably accurate, noninvasive, fast, and very useful in planning surgical or endoscopic intervention.
The most predictive endosonographic feature of chronic pancreatitis is the presence of stones. Other suggestive features include the following:
Visible side branches
An irregular main pancreatic duct
Hyperechoic foci and strands
Dilation of the main pancreatic duct
Hyperechoic margins of the main pancreatic duct
See Workup for more detail.
Treatment is typically directed at the underlying cause of the pancreatitis and to relieve pain and malabsorption.
Pancreatic enzyme supplementation may be helpful in reducing pain. The hypothesis is that stimulation of the pancreas by food causes pain. Cholecystokinin (CCK) is one of the possible mediators of this response. When exogenous pancreatic enzymes are taken with a meal, CCK-releasing factors are degraded and CCK release in response to a meal is reduced. This decreases pancreatic stimulation and pain.
If conventional medical therapy is unsuccessful and the patient has severe, intractable pain, celiac ganglion blockade can be considered. This approach tries to alleviate pain by modifying afferent sensory nerves in the celiac plexus, using agents that anesthetize, reduce inflammation, or destroy nerve fibers.
Endoscopic therapy aimed at decompressing an obstructed pancreatic duct can be associated with pain relief in some patients. The rationale for this approach is based on the hypothesis that ductal hypertension due to strictures of the main pancreatic duct leads to pain.[3, 4]
The choice of operation depends on the clinical problem and the preoperative assessment of the abnormality. In general, the approach aims either to improve pancreatic duct drainage or to resect the diseased organ. Data suggest that surgical drainage of the pancreatic duct is more effective than endoscopic drainage in patients with obstruction of the pancreatic duct due to chronic pancreatitis.
In patients with a dilated pancreatic duct, a Roux-en-Y side-to-side pancreaticojejunostomy is indicated. If the disease is limited to the head of the pancreas, a Whipple operation (pancreaticoduodenectomy) can produce good results.
See Treatment and Medication for more detail.
Chronic pancreatitis is commonly defined as a continuing, chronic, inflammatory process of the pancreas, characterized by irreversible morphologic changes. This chronic inflammation can lead to chronic abdominal pain and/or impairment of endocrine and exocrine function of the pancreas. (See Pathophysiology and Etiology.)
Chronic pancreatitis usually is envisioned as an atrophic fibrotic gland with dilated ducts and calcifications. However, findings on conventional diagnostic studies may be normal in the early stages of chronic pancreatitis, as the inflammatory changes can be seen only by histologic examination (see the images below). (See Workup.)
By definition, chronic pancreatitis is a completely different process from acute pancreatitis. In acute pancreatitis, the patient presents with acute and severe abdominal pain, nausea, and vomiting. The pancreas is acutely inflamed (neutrophils and edema), and the serum levels of pancreatic enzymes (amylase and lipase) are elevated. Full recovery is observed in most patients with acute pancreatitis, whereas in chronic pancreatitis, the primary process is a chronic, irreversible inflammation (monocyte and lymphocyte) that leads to fibrosis with calcification. (See Pathophysiology, Etiology, Presentation, and Workup.)
The patient with chronic pancreatitis clinically presents with chronic abdominal pain and normal or mildly elevated pancreatic enzyme levels. When the pancreas loses its endocrine and exocrine function, the patient presents with diabetes mellitus and steatorrhea. (See Presentation and Workup.)
For patient education information, see the Digestive Disorders Center and the Cancer Center, as well as Pancreatitis and Pancreatic Cancer.
Whatever the etiology of chronic pancreatitis, pancreatic fibrogenesis appears to be a typical response to injury. This involves a complex interplay of growth factors, cytokines, and chemokines, leading to deposition of extracellular matrix and fibroblast proliferation. In pancreatic injury, local expression and release of transforming growth factor beta (TGF-beta) stimulates the growth of cells of mesenchymal origin and enhances the synthesis of extracellular matrix proteins, such as collagens, fibronectin, and proteoglycans.
Evidence indicates involvement of distinct chemokines in the initiation and perpetuation of chronic pancreatitis.
The cause of chronic pancreatitis usually is metabolic in nature. The proposed pathologic mechanisms of chronic pancreatitis are as follows:
Intraductal plugging and obstruction - Eg, ethanol (ETOH) abuse, stones, tumors
Direct toxins and toxic metabolites - These act on the pancreatic acinar cell to stimulate the release of cytokines, which stimulate the stellate cell to produce collagen and to establish fibrosis; cytokines also act to stimulate inflammation by neutrophils, macrophages, and lymphocytes (eg, ETOH, tropical sprue)
Oxidative stress - Eg, idiopathic pancreatitis
Necrosis-fibrosis - Recurrent acute pancreatitis that heals with fibrosis
Ischemia - From obstruction and fibrosis; important in exacerbating or perpetuating disease rather than in initiating disease
Autoimmune disorders - Chronic pancreatitis has been found in association with other autoimmune diseases, such as Sjögren syndrome, primary biliary cirrhosis, and renal tubular acidosis.
Secondary forms of autoimmune chronic pancreatitis are associated with primary biliary cirrhosis, primary sclerosing cholangitis, and Sjögren syndrome.
While alcohol greatly influences the understanding of its pathophysiology because it is the most common etiology (60-70%), approximately 20-30% of cases are idiopathic and 10% of cases are due to rare diseases.
Autoimmune pancreatitis is a more recently described entity. Clinical characteristics include symptomatic or asymptomatic, diffuse enlargement of the pancreas, diffuse and irregular narrowing of the main pancreatic duct, increased circulating levels of gamma globulin, the presence of autoantibodies, and a possible association with other autoimmune diseases. Fibrosis with lymphocytic infiltration is seen on pathology. The disorder is associated with elevated immunoglobulin G4 (IgG4) concentrations.
In a study of 51 patients with autoimmune pancreatitis, Kawa et al suggested that a strong link exists between pancreatic stone formation and the recurrence of autoimmune pancreatitis and that following several recurrences, this disease may develop into chronic pancreatitis. In the study, the authors found that during a long-term follow-up period, 21 patients suffered a recurrence of the condition and 9 of the 51 patients developed pancreatic stones.
The investigators also found that the stones developed more frequently in the recurrence group (7 [33%] of 21 patients) than in the other patients (2 [7%] of 30 patients). In addition, within a group of 175 patients with chronic hepatitis, 13 patients were found to have high serum concentrations of IgG4.
Alcoholic chronic pancreatitis
Excessive alcohol consumption is the most common cause of pancreatitis, accounting for about 60% of all cases.
In the affected gland, alcohol appears to increase protein secretion from acinar cells while decreasing fluid and bicarbonate production from ductal epithelial cells. The resulting viscous fluid results in proteinaceous debris becoming inspissated within the lumen, causing ductular obstruction, upstream acinar atrophy, and fibrosis. GP2, which is secreted from the acinar cell and is homologous to a protein involved in renal tubular casts, is an integral component of these ductal plugs.
Lithostathine (formerly called pancreatic stone protein), which also is produced by acinar cells, accounts for about 5% of secretory protein and inhibits the growth of calcium carbonate crystals. Abnormal lithostathine S1, whether inherited or acquired through trypsin digestion, appears to play a role in stone formation; it is insoluble at the neutral pH of pancreatic juice and is the major constituent of pancreatic stones.
A competing theory suggests that the persistent demands of metabolizing alcohol (and probably other xenobiotics, such as drugs, tobacco smoke, environmental toxins, and pollution) cause oxidative stress within the pancreas and may lead to cellular injury and organ damage, especially in the setting of malnutrition. Oxidative and nonoxidative pathways metabolize ethanol. Alcohol dehydrogenase oxidatively metabolizes ethanol first to acetaldehyde and then to acetate. When the alcohol concentration increases, cytochrome P-450 2E1 is induced to meet the metabolic demands.
Although these reactions occur principally in the liver, further increases in ethanol concentration induce pancreatic cytochrome P-450 2E1, and the level of acetate within the pancreas begins to approach that observed in the liver. Reactive oxygen species produced by this reaction may overwhelm cellular defenses and damage important cellular processes.
Although nonoxidative metabolism of ethanol is a minor pathway, the fatty acid ethyl esters produced by this reaction may cause cellular injury and are synthesized in the pancreas to a greater extent than in other organ systems.
Because fewer than 5-10% of people with alcoholism develop chronic pancreatitis, another factor or factors must place these individuals at risk. Researchers have studied genetic polymorphisms of ethanol-oxidizing enzymes, but to date, none have correlated with a susceptibility to alcohol-induced pancreatitis.
A mutation in the gene encoding the serine protease inhibitor, Kazal type 1, has been identified in patients with chronic pancreatitis. The N34S mutation was detected in 5.8% of 274 patients with alcoholic chronic pancreatitis, compared with 1.0% of people with alcoholism without pancreatitis. Although all patients were heterozygous for the mutation, it provides evidence for abnormalities in the pancreatic protease/protease inhibitor system playing a role in the pathogenesis of alcoholic chronic pancreatitis.
Several inherited disorders also are considered metabolic in origin. Hereditary pancreatitis is an autosomal dominant disorder with an 80% penetrance, accounting for about 1% of cases. Research of families with hereditary pancreatitis has led to the identification of several mutations in the cationic trypsinogen gene on chromosome 7. These mutations apparently render the activated enzyme resistant to second-line proteolytic control mechanisms. Mutations were found in the pancreatic secretory serine protease inhibitor Kazal type 1 (SPINK1) gene in 18 of 96 patients with idiopathic or hereditary chronic pancreatitis.
Cystic fibrosis in pancreatitis
Cystic fibrosis, one of the most common genetic abnormalities, is an autosomal recessive disorder accounting for a small percent of patients with chronic pancreatitis. The cystic fibrosis transmembrane regulator (CFTR) gene transcribes a protein important in regulating chloride transport across cellular membranes.
Several hundred mutations of the CFTR gene have been identified, and the clinical manifestation of any given mutation depends on how severely it affects the protein's ability to regulate chloride transport. Different mutations in CFTR are associated with different functional statuses of the exocrine pancreas.
Specific CFTR genotypes are significantly associated with pancreatitis. Patients with genotypes associated with mild phenotypic effects have a greater risk of developing pancreatitis than do patients with genotypes associated with moderate-severe phenotypes.
Idiopathic chronic pancreatitis
This form of chronic pancreatitis accounts for approximately 30% of cases. It has been arbitrarily divided into early onset and late-onset forms. While the cause of idiopathic chronic pancreatitis is not yet known, some evidence points to atypical genetic mutations in CFTR, cationic trypsinogen, and other proteins.
Congenital abnormalities in chronic pancreatitis
Congenital abnormalities, such as pancreas divisum and annular pancreas divisum, are uncommon (even rare) causes of chronic pancreatitis and usually require an additional factor to induce chronic pancreatitis. For example, while pancreas divisum usually does not cause chronic pancreatitis, patients with divisum and minor papilla stenosis are at risk. In these patients, clear evidence of disease exists in the dorsal pancreas, whereas the ventral pancreas is normal histologically.
Acquired obstructive chronic pancreatitis
Acquired obstructive forms typically result from blunt abdominal trauma or accidents involving motor vehicles, bicycles, horses, or, on occasion, severe falls. In these cases, the pancreas is whiplashed against the spine, causing trauma to the ductal system and resulting in a stricture close to the surgical genu. In rare instances, chronic inflammatory conditions affecting the duodenum, or primarily the duodenal papilla, can induce fibrosis and papillary stenosis in a subset of patients, leading to chronic pancreatitis.
Other causes of chronic pancreatitis include the following:
Hyperlipidemia (usually type I and type V) - However, hyperlipidemia usually presents with repeated attacks of acute pancreatitis
Hypercalcemia due to hyperparathyroidism - Now is a rare cause of chronic pancreatitis, probably because automation of serum chemistries reveals hypercalcemia before it results in pancreatitis
Nutritional, or tropical, chronic pancreatitis - Rare in the United States, but an important cause of disease in other parts of the world
Medications - An infrequent, or possibly underrecognized, cause of chronic pancreatitis
Obstruction of the flow of pancreatic juice can cause chronic pancreatitis. Obstructive forms account for less than 10% of cases and may be congenital or acquired.
Based on estimates from hospital discharge data in the United States, approximately 87,000 cases of pancreatitis occur annually.
Comparing the hospital admissions data from several cities around the globe, the overall frequency is similar. Expressed as number of cases per 1000 hospital admissions, the value for Marseille is 3.1; for Cape Town, 4.4; for Sao Paulo, 4.9; and for Mexico City, 4.4. When the data from several centers were compared over time, the incidence of chronic pancreatitis from 1945-1985 appeared to be increasing.
Race-, sex-, and age-related demographics
Hospitalization rates for blacks are 3 times higher than for whites in the United States. In population studies, males are affected more commonly than females (6.7 vs 3.2 per 100,000 population).
Differences in the hospitalization rates of patients with chronic pancreatitis exist with respect to sex. Rates in males peak between ages 45 and 54 years and then decline; female rates reach a plateau, which remains stable after age 35 years.
Sex differences with respect to etiology also exist. Alcohol-induced illness is more prevalent in males, idiopathic and hyperlipidemic-induced pancreatitis is more prevalent in females, and equal sex ratios are observed in chronic pancreatitis associated with hereditary pancreatitis.
In aggregate, the mean age at diagnosis is at age 46 years, plus or minus 13 years. In idiopathic chronic pancreatitis, a bimodal age distribution has been reported, designated as the early onset form (median age 19.2 y) and the late-onset form (median age 56.2 y).
The prognostic factors associated with chronic pancreatitis are age at diagnosis, smoking, continued use of alcohol, and the presence of liver cirrhosis.
The overall survival rate is 70% at 10 years and 45% at 20 years. In an international study, 559 deaths occurred among patients with chronic pancreatitis, compared with an expected number of 157, which creates a standard mortality ratio of 3.6. Taking the opposite view, the 10-year mortality rate is 30%, and the 20-year mortality rate is 55%. The risk of developing pancreatic cancer is approximately 4% at 20 years.
The most common complications of chronic pancreatitis are pseudocyst formation and mechanical obstruction of the duodenum and common bile duct. Less frequent complications include pancreatic ascites or pleural effusion, splenic vein thrombosis with portal hypertension, and pseudoaneurysm formation of the splenic artery.
A pseudocyst is a collection of pancreatic juice enclosed by a wall of fibrous or granulation tissue. It arises as a consequence of acute pancreatitis, pancreatic trauma, or chronic pancreatitis. The clinical challenge is to diagnose a cystic pancreatic structure correctly as a pseudocyst. As many as 5% of cysts are retention cysts, another 5% of these cysts are either congenital in origin or acquired (as in von Hippel-Lindau syndrome), and 10% are neoplastic in origin (mucinous vs serous cyst).
Pseudocysts develop in approximately 10% of patients with chronic pancreatitis. They develop as a result of ductal disruptions rather than from peripancreatic fluid accumulations that lead to pseudocyst formation in the setting of acute pancreatitis. Pseudocysts may be single or multiple and can be small or large, and they can be located either within or outside of the pancreas. Most pseudocysts communicate with the pancreatic ductal system and contain high concentrations of digestive enzymes.
The walls of pseudocysts are formed by adjacent structures, such as the stomach, transverse mesocolon, gastrocolic omentum, and pancreas. The lining of pancreatic pseudocysts consists of fibrous and granulation tissue; the lack of an epithelial lining distinguishes pseudocysts from true cystic lesions of the pancreas. Most pseudocysts are asymptomatic. They can, however, produce a wide range of clinical problems, depending upon the location and extent of the fluid collection.
Expansion of the pseudocyst can produce abdominal pain, duodenal or biliary obstruction, vascular occlusion, or fistula formation into adjacent viscera, the pleural space, or pericardium. Spontaneous infection with abscess formation can occur. (See the images below.)
Digestion of an adjacent vessel can result in a pseudoaneurysm, which can produce a sudden expansion of the cyst or gastrointestinal bleeding due to bleeding into the pancreatic duct (hemosuccus pancreaticus).
Pancreatic ascites and pleural effusion can result from disruption of the pancreatic duct, leading to fistula formation to the abdomen or chest, or rupture of a pseudocyst with tracking of pancreatic juice into the peritoneal cavity or pleural space.
The indications for drainage of pseudocysts include rapid enlargement, compression of surrounding structures, pain, or signs of infection. Endoscopic retrograde pancreatograms may be helpful prior to drainage to rule out a stricture of the pancreatic duct, which can lead to persistent drainage from the pseudocyst.
Bile obstruction and duodenal obstruction
Symptomatic obstruction of the bile duct and/or duodenum develops in 5-10% of patients with chronic pancreatitis. Postprandial pain and early satiety are characteristic of duodenal obstruction, while pain and abnormal liver function test results (including hyperbilirubinemia) are suggestive of a bile duct stricture. These complications are most commonly seen in patients with dilated pancreatic ducts; they are either due to inflammation and fibrosis in the head of the pancreas or are the result of a pseudocyst.
Drainage of an obstructing pseudocyst can be accomplished surgically by gastrojejunostomy or choledochoenterostomy. Endoscopic stenting may be helpful for benign bile duct strictures.
Additional complications of chronic pancreatitis
Diabetes mellitus is a late manifestation in about one third of patients. The tendency to develop ketoacidosis is low.
The presence of the splenic vein at the posterior surface of the pancreas predisposes it to thrombosis from adjacent pancreatic inflammation. Patients who are affected can develop gastric varices as a result of associated portal hypertension. Splenectomy is usually curative for patients who develop bleeding from gastric varices.
Pseudoaneurysm is rare, but it can be a deadly complication. Affected vessels, including the splenic, hepatic, gastroduodenal, and pancreaticoduodenal arteries, are in close proximity to the pancreas. Surgery for bleeding pseudoaneurysms is challenging and associated with high morbidity and mortality.
Vege SS, Ziring B, Jain R, Moayyedi P, for the Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015 Apr. 148(4):819-22. [Medline].
Kaufman M, Singh G, Das S, Concha-Parra R, Erber J, Micames C, et al. Efficacy of endoscopic ultrasound-guided celiac plexus block and celiac plexus neurolysis for managing abdominal pain associated with chronic pancreatitis and pancreatic cancer. J Clin Gastroenterol. 2010 Feb. 44(2):127-34. [Medline].
Gadroy FX, Ponchon T, Roda R, et al. Endoscopic treatment of chronic pancreatitis: long-term results. Gastrointest Endosc. Apr 2006. 63(5):AB312.
Cahen DL, Gouma DJ, Nio Y, et al. Endoscopic versus surgical drainage of the pancreatic duct in chronic pancreatitis. N Engl J Med. 2007 Feb 15. 356(7):676-84. [Medline].
Büchler MW, Martignoni ME, Friess H, Malfertheiner P. A proposal for a new clinical classification of chronic pancreatitis. BMC Gastroenterol. 2009 Dec 14. 9:93. [Medline]. [Full Text].
Pezzilli R. Etiology of chronic pancreatitis: has it changed in the last decade?. World J Gastroenterol. 2009 Oct 14. 15(38):4737-40. [Medline]. [Full Text].
Kawa S, Hamano H, Ozaki Y, et al. Long-term follow-up of autoimmune pancreatitis: characteristics of chronic disease and recurrence. Clin Gastroenterol Hepatol. 2009 Nov. 7(11 Suppl):S18-22. [Medline].
Schmitt F, Le Henaff G, Piloquet H, et al. Hereditary pancreatitis in children: surgical implications with special regard to genetic background. J Pediatr Surg. 2009 Nov. 44(11):2078-82. [Medline].
Ooi CY, Dorfman R, Cipolli M, et al. Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology. 2011 Jan. 140(1):153-61. [Medline].
Tezuka K, Makino T, Hirai I, Kimura W. Groove pancreatitis. Dig Surg. 2010. 27(2):149-52. [Medline].
Saftoiu A, Popescu C, Cazacu S, et al. Power Doppler endoscopic ultrasonography for the differential diagnosis between pancreatic cancer and pseudotumoral chronic pancreatitis. J Ultrasound Med. 2006 Mar. 25(3):363-72. [Medline]. [Full Text].
Kalb B, Martin DR, Sarmiento JM, Erickson SH, Gober D, Tapper EB, et al. Paraduodenal Pancreatitis: Clinical Performance of MR Imaging in Distinguishing from Carcinoma. Radiology. 2013 Nov. 269(2):475-81. [Medline].